Molecular pathways and therapeutic targets in lung cancer

Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasin...

Full description

Saved in:
Bibliographic Details
Published inOncotarget Vol. 5; no. 6; pp. 1392 - 1433
Main Authors Shtivelman, Emma, Hensing, Thomas, Simon, George R., Dennis, Phillip A., Otterson, Gregory A., Bueno, Raphael, Salgia, Ravi
Format Journal Article
LanguageEnglish
Published United States Impact Journals LLC 30.03.2014
Subjects
Animals
Antineoplastic Agents - therapeutic use
Humans
Molecular Targeted Therapy
Neoplasm Proteins - antagonists & inhibitors
Neoplasm Proteins - metabolism
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - pathology
Review
Signal Transduction - drug effects
Online AccessGet full text
ISSN1949-2553
1949-2553
DOI10.18632/oncotarget.1891

Cover

Abstract Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.
AbstractList Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.
Author Bueno, Raphael
Simon, George R.
Otterson, Gregory A.
Shtivelman, Emma
Dennis, Phillip A.
Hensing, Thomas
Salgia, Ravi
AuthorAffiliation 1 Cancer Commons, Palo Alto, CA, United States of America
7 Department of Medicine, Section of Hematology/Oncology, University of Chicago, United States of America
2 Northshore University Health System and University of Chicago, United States of America
4 Johns Hopkins University School of Medicine, United States of America
3 MD Anderson Cancer Center, United States of America
5 Ohio State University Comprehensive Cancer Center, United States of America
6 Brigham & Women's Hospital, Harvard Medical School, United States of America
AuthorAffiliation_xml – name: 1 Cancer Commons, Palo Alto, CA, United States of America
– name: 4 Johns Hopkins University School of Medicine, United States of America
– name: 3 MD Anderson Cancer Center, United States of America
– name: 5 Ohio State University Comprehensive Cancer Center, United States of America
– name: 2 Northshore University Health System and University of Chicago, United States of America
– name: 7 Department of Medicine, Section of Hematology/Oncology, University of Chicago, United States of America
– name: 6 Brigham & Women's Hospital, Harvard Medical School, United States of America
Author_xml – sequence: 1
  givenname: Emma
  surname: Shtivelman
  fullname: Shtivelman, Emma
  organization: Cancer Commons, Palo Alto, CA, United States of America
– sequence: 2
  givenname: Thomas
  surname: Hensing
  fullname: Hensing, Thomas
  organization: Northshore University Health System and University of Chicago, United States of America
– sequence: 3
  givenname: George R.
  surname: Simon
  fullname: Simon, George R.
  organization: MD Anderson Cancer Center, United States of America
– sequence: 4
  givenname: Phillip A.
  surname: Dennis
  fullname: Dennis, Phillip A.
  organization: Johns Hopkins University School of Medicine, United States of America
– sequence: 5
  givenname: Gregory A.
  surname: Otterson
  fullname: Otterson, Gregory A.
  organization: Ohio State University Comprehensive Cancer Center, United States of America
– sequence: 6
  givenname: Raphael
  surname: Bueno
  fullname: Bueno, Raphael
  organization: Brigham & Women's Hospital, Harvard Medical School, United States of America
– sequence: 7
  givenname: Ravi
  surname: Salgia
  fullname: Salgia, Ravi
  organization: Department of Medicine, Section of Hematology/Oncology, University of Chicago, United States of America
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24722523$$D View this record in MEDLINE/PubMed
BookMark eNp1Uc1PwyAUJ2bGzbm7J9OjlynQlsLFxCx-JTNe9ExeKd0wHUygmv33dm7TaeI78F7g_T7C7xj1rLMaoVOCLwhnKb10VrkIfqZjdyHIARoQkYkxzfO0tzf30SiEV9xVnhWciiPUp1lBaU7TARKPrtGqbcAnS4jzD1iFBGyVxLn2sNRtNCrZaITE2KRp7SxRYJX2J-iwhibo0bYP0cvtzfPkfjx9unuYXE_HKmM0jlmZAwZepzwTvK5YSYtaVaQqSQoZZ7wAAlixXBVVwerObiVUWWCtGa1Z3nkcoqsN77ItF7pS2kYPjVx6swC_kg6M_P1izVzO3LvMcCooxR3B-ZbAu7dWhygXJijdNGC1a4MkORU85aI7huhsX-tbZPdf3QLbLCjvQvC6lspEiMatpU0jCZZf2cifbOQ6mw6I_wB33P9CPgEvb5ZX
CitedBy_id crossref_primary_10_3390_molecules24030407
crossref_primary_10_2174_0929866529666220110143520
crossref_primary_10_1007_s12079_020_00565_4
crossref_primary_10_7314_APJCP_2015_16_10_4147
crossref_primary_10_1002_cncy_21714
crossref_primary_10_4236_jbm_2024_124009
crossref_primary_10_3892_etm_2018_5845
crossref_primary_10_1038_s41598_018_38004_5
crossref_primary_10_1186_s12890_020_01317_1
crossref_primary_10_3233_CBM_230188
crossref_primary_10_3892_or_2017_5571
crossref_primary_10_7554_eLife_09462
crossref_primary_10_1016_j_jtho_2021_03_024
crossref_primary_10_1186_s12890_020_01276_7
crossref_primary_10_1007_s11060_023_04519_9
crossref_primary_10_1186_s12885_018_4103_5
crossref_primary_10_18632_oncotarget_3818
crossref_primary_10_1002_jbt_21914
crossref_primary_10_1002_jcla_24536
crossref_primary_10_1002_cbdv_202402083
crossref_primary_10_1080_14737159_2016_1181545
crossref_primary_10_1101_cshperspect_a038240
crossref_primary_10_3390_molecules25040895
crossref_primary_10_1002_cbin_11862
crossref_primary_10_1007_s13277_015_4335_9
crossref_primary_10_1155_2022_3472745
crossref_primary_10_1016_j_bbrc_2017_11_075
crossref_primary_10_1124_jpet_114_216333
crossref_primary_10_1039_C8CC01154K
crossref_primary_10_1016_j_critrevonc_2021_103454
crossref_primary_10_1038_nrclinonc_2015_108
crossref_primary_10_18632_oncotarget_8440
crossref_primary_10_1007_s00428_019_02597_7
crossref_primary_10_1016_j_bbcan_2015_08_002
crossref_primary_10_18632_oncotarget_13974
crossref_primary_10_18632_oncotarget_10985
crossref_primary_10_1093_g3journal_jkab365
crossref_primary_10_3389_fmolb_2024_1502509
crossref_primary_10_1016_S1470_2045_16_30123_1
crossref_primary_10_1016_j_bios_2018_04_013
crossref_primary_10_1371_journal_pone_0181081
crossref_primary_10_1016_j_compbiomed_2024_109091
crossref_primary_10_1111_cpr_12364
crossref_primary_10_3892_ol_2017_6729
crossref_primary_10_3390_ijms21082774
crossref_primary_10_18632_oncotarget_2595
crossref_primary_10_1080_10715762_2019_1642472
crossref_primary_10_18632_oncotarget_4254
crossref_primary_10_1097_JCMA_0000000000000225
crossref_primary_10_18632_oncotarget_6312
crossref_primary_10_1016_j_genrep_2020_100633
crossref_primary_10_3390_molecules27041158
crossref_primary_10_18632_oncotarget_8053
crossref_primary_10_17546_msd_493329
crossref_primary_10_3390_ijms21186957
crossref_primary_10_1016_j_ymeth_2020_05_023
crossref_primary_10_1126_sciadv_abn1229
crossref_primary_10_1016_j_arr_2024_102315
crossref_primary_10_3390_jmp2020016
crossref_primary_10_1186_s12967_022_03565_7
crossref_primary_10_18632_oncotarget_11109
crossref_primary_10_3390_cancers12020291
crossref_primary_10_3390_ijms24021506
crossref_primary_10_3892_ol_2019_10762
crossref_primary_10_1007_s11010_016_2822_y
crossref_primary_10_17546_msd_569279
crossref_primary_10_1109_JBHI_2023_3290006
crossref_primary_10_1038_srep39001
crossref_primary_10_18632_oncotarget_22860
crossref_primary_10_1016_j_intimp_2020_106856
crossref_primary_10_1111_ajco_12586
crossref_primary_10_1016_j_jer_2023_100091
crossref_primary_10_18632_oncotarget_13195
crossref_primary_10_18632_oncotarget_15132
crossref_primary_10_18632_oncotarget_3727
crossref_primary_10_31857_S0016675824050053
crossref_primary_10_1158_1078_0432_CCR_19_1376
crossref_primary_10_1007_s12032_022_01738_4
crossref_primary_10_1016_j_semcancer_2017_11_019
crossref_primary_10_1111_1759_7714_12492
crossref_primary_10_1016_j_tranon_2018_04_006
crossref_primary_10_1155_2022_3793318
crossref_primary_10_1002_mp_16233
crossref_primary_10_1016_j_ejphar_2022_175479
crossref_primary_10_1111_jcmm_17214
crossref_primary_10_5702_massspec_S16_14
crossref_primary_10_1088_1361_6560_aad648
crossref_primary_10_1021_acs_jmedchem_9b00855
crossref_primary_10_1002_cbdv_202401904
crossref_primary_10_1016_j_csbj_2019_02_003
crossref_primary_10_1002_jso_23738
crossref_primary_10_1186_s40169_015_0064_3
crossref_primary_10_1038_s41598_019_45589_y
crossref_primary_10_3390_cells13181558
crossref_primary_10_1111_1759_7714_15495
crossref_primary_10_1177_09760016241298053
crossref_primary_10_3390_molecules27249005
crossref_primary_10_3892_ijo_2020_5024
crossref_primary_10_18632_oncotarget_21317
crossref_primary_10_3390_ijms22116131
crossref_primary_10_1016_j_semcancer_2018_03_004
crossref_primary_10_3390_molecules22040578
crossref_primary_10_15406_ijcam_2017_08_00254
crossref_primary_10_1038_s41598_017_05047_z
crossref_primary_10_1002_cbdv_202402963
crossref_primary_10_1016_j_canlet_2018_10_035
crossref_primary_10_1093_carcin_bgac098
crossref_primary_10_1302_0301_620X_99B4_BJJ_2016_0872_R1
crossref_primary_10_1016_j_clinthera_2024_04_006
crossref_primary_10_1016_j_humpath_2016_02_027
crossref_primary_10_1016_j_yexmp_2019_104354
crossref_primary_10_1016_j_jddst_2023_104588
crossref_primary_10_1016_j_dmpk_2015_11_008
crossref_primary_10_1177_1078155220931926
crossref_primary_10_2174_0929866528666210930170624
crossref_primary_10_1016_j_jtho_2016_08_138
crossref_primary_10_1007_s12032_015_0672_1
crossref_primary_10_1007_s11033_020_05744_5
crossref_primary_10_3390_ijms19030767
crossref_primary_10_1371_journal_pcbi_1007869
crossref_primary_10_1080_14789450_2019_1654861
crossref_primary_10_1080_15384047_2015_1046649
crossref_primary_10_3390_cancers15215219
crossref_primary_10_1021_acsnano_8b01670
crossref_primary_10_1002_adfm_201910402
crossref_primary_10_1016_j_bbcan_2016_07_002
crossref_primary_10_1267_ahc_21_00075
crossref_primary_10_3390_genes10090670
crossref_primary_10_1093_jpp_rgab056
crossref_primary_10_2174_1573407219666221024142326
crossref_primary_10_18632_oncotarget_7732
crossref_primary_10_1186_s13293_024_00634_y
crossref_primary_10_1080_21655979_2020_1735611
crossref_primary_10_1186_s12859_019_3218_2
crossref_primary_10_18632_oncotarget_23474
crossref_primary_10_18632_oncotarget_8021
crossref_primary_10_1038_s41598_019_48372_1
crossref_primary_10_1007_s11010_020_03973_7
crossref_primary_10_1371_journal_pone_0198203
crossref_primary_10_1016_j_bios_2016_02_009
crossref_primary_10_1039_C7BM00035A
crossref_primary_10_1016_j_prp_2019_152591
crossref_primary_10_1111_his_13333
crossref_primary_10_1134_S1022795424700133
crossref_primary_10_2174_1386207324666210712092649
crossref_primary_10_1039_C6NR03143A
crossref_primary_10_3389_fonc_2016_00240
crossref_primary_10_1517_17460441_2015_971007
crossref_primary_10_1016_j_gene_2018_01_003
crossref_primary_10_1016_j_sjbs_2023_103596
crossref_primary_10_3390_jcm9061884
crossref_primary_10_1080_21655979_2021_1950278
Cites_doi 10.1038/sj.bjc.6690152
10.1128/MCB.24.16.7130-7139.2004
10.1371/journal.pmed.0020073
10.1038/ng.465
10.1158/0008-5472.CAN-04-2561
10.1038/nature12205
10.1101/gr.133645.111
10.1371/journal.pmed.0020313
10.1016/j.lungcan.2005.12.014
10.1093/jnci/djt072
10.1016/j.lungcan.2004.10.010
10.1016/j.ccr.2013.05.021
10.1097/JTO.0b013e318283dcc0
10.1097/JTO.0b013e318283d958
10.1158/2159-8274.CD-11-0005
10.1038/bjc.1996.646
10.1007/s10637-012-9881-z
10.1016/j.lungcan.2012.06.005
10.1111/j.1582-4934.2009.00991.x
10.1073/pnas.1207310109
10.1158/2159-8290.CD-12-0112
10.1016/j.lungcan.2009.11.019
10.1038/nm.3388
10.1096/fj.06-5947rev
10.1517/14712598.2011.626762
10.1016/j.cell.2013.03.025
10.1016/j.ccr.2014.01.008
10.1007/s00280-012-1831-0
10.1172/JCI67313
10.1200/JCO.2006.08.3311
10.1016/S1470-2045(11)70184-X
10.1053/hupa.2001.21133
10.1016/S1470-2045(10)70112-1
10.1371/journal.pone.0029907
10.1002/humu.20730
10.1073/pnas.251407098
10.1007/s10585-008-9200-4
10.18632/oncotarget.1542
10.1158/1078-0432.CCR-08-3328
10.1158/2159-8290.CD-11-0046
10.1038/sj.bjc.6602258
10.1158/0008-5472.CAN-12-3932
10.1038/ncomms2660
10.1158/1078-0432.CCR-12-3696
10.1200/JCO.2010.33.1280
10.1158/2159-8290.CD-12-0108
10.1097/JTO.0b013e3181913e0e
10.1158/0008-5472.CAN-07-5084
10.1200/JCO.2012.47.4189
10.1073/pnas.0709662105
10.1016/j.cell.2012.08.024
10.1038/nature06358
10.1016/j.lungcan.2003.09.010
10.1073/pnas.1320956111
10.1056/NEJMoa1214886
10.1016/j.ccr.2010.04.026
10.1016/j.cell.2007.11.025
10.1200/JCO.2011.38.9411
10.1200/JCO.2010.34.0570
10.1158/1078-0432.CCR-12-1558
10.1038/nm.2473
10.1016/j.ccr.2009.11.022
10.1056/NEJMoa0706550
10.1152/ajpcell.00226.2003
10.1097/JTO.0b013e3182307f17
10.1200/JCO.2005.05.5335
10.1200/JCO.2012.43.4522
10.1158/0008-5472.CAN-12-1611
10.1016/j.celrep.2013.09.018
10.1073/pnas.0710370104
10.1073/pnas.97.10.5462
10.1126/science.1141478
10.1038/35041577
10.1016/j.ccr.2013.09.012
10.1038/431525b
10.1126/science.2157284
10.18632/oncotarget.763
10.1056/NEJMoa0909530
10.1016/j.semcancer.2004.04.015
10.1016/j.cell.2013.09.041
10.1016/j.lungcan.2012.10.006
10.1200/JCO.2012.45.8703
10.1056/NEJMoa1200694
10.1097/01243894-200602000-00012
10.1038/328170a0
10.1002/cncr.27575
10.1200/JCO.2008.18.7658
10.1038/nm.2658
10.1200/JCO.2011.36.6799
10.1097/JTO.0b013e3182a47162
10.1200/JCO.2011.40.7783
10.1309/P5ABR5KQ89RNJTFH
10.1200/JCO.2012.45.2029
10.1093/annonc/mdh031
10.1242/dev.034884
10.1038/nchembio.1184
10.1158/1078-0432.CCR-12-3173
10.1158/0008-5472.CAN-04-4235
10.1371/journal.pone.0066933
10.1016/j.cell.2012.08.029
10.1200/JCO.2009.26.7609
10.1158/1078-0432.CCR-10-2692
10.1097/JTO.0b013e3181e2a2bc
10.1038/nature12796
10.1038/nature05945
10.1177/1758834011408636
10.1016/j.ccr.2013.10.003
10.1016/S1470-2045(13)70254-7
10.1158/0008-5472.CAN-12-3950
10.1245/s10434-009-0808-7
10.1056/NEJMoa0810699
10.1073/pnas.1019559108
10.1101/gad.205542.112
10.1016/S1470-2045(12)70086-4
10.1158/1078-0432.CCR-09-0070
10.1084/jem.192.7.1027
10.1093/annonc/mdr564
10.1158/0008-5472.CAN-04-2650
10.1016/j.ccr.2012.12.008
10.1016/j.ccr.2012.02.008
10.1371/journal.pone.0055637
10.1186/1471-2407-7-128
10.1200/JCO.2009.22.6993
10.1016/S1470-2045(12)70489-8
10.1038/nature07423
10.4161/cc.7.5.5485
10.2353/jmoldx.2007.060182
10.1073/pnas.1203530109
10.1200/JCO.2011.38.4032
10.1158/1078-0432.CCR-12-0838
10.1200/JCO.2011.40.9433
10.1016/j.cytogfr.2005.05.010
10.1158/1078-0432.CCR-11-2906
10.1016/j.cell.2011.08.017
10.1056/NEJMoa1215530
10.1016/j.stem.2011.04.003
10.1158/1078-0432.CCR-12-2982
10.1038/nature11404
10.1038/367375a0
10.1038/nm.2644
10.1158/1535-7163.MCT-11-0750
10.1038/onc.2009.198
10.1038/sj.onc.1203815
10.1038/ng.2396
10.1002/ijc.22143
10.1038/srep02560
10.1158/1078-0432.CCR-09-1365
10.1371/journal.pmed.0030420
10.1200/JCO.2012.44.1477
10.1126/science.1092472
10.1038/nature01493
10.1016/j.cell.2013.08.015
10.1158/2159-8290.CD-12-0440
10.1371/journal.pone.0037775
10.1073/pnas.0708286104
10.1158/0008-5472.CAN-09-3106
10.1200/JCO.2008.19.9331
10.1073/pnas.1319583110
10.1016/j.humpath.2005.05.006
10.1016/S1470-2045(12)70474-6
10.1200/JCO.2012.47.2787
10.1016/S1470-2045(13)70142-6
10.1016/S1470-2045(08)70206-7
10.1158/1078-0432.CCR-09-1624
10.1200/JCO.2009.24.7049
10.1002/ijc.10795
10.1056/NEJMoa1302369
10.1016/S1470-2045(13)70355-3
10.1038/nrc2088
10.1038/nature08822
10.1038/386852a0
10.1002/ijc.21155
10.1126/scitranslmed.3007205
10.1158/1078-0432.CCR-11-2967
10.1158/1078-0432.CCR-12-2694
10.1016/j.ccr.2012.11.007
10.1016/j.ydbio.2008.02.035
10.1007/s00280-013-2132-y
10.18632/oncotarget.550
10.1016/j.lungcan.2009.11.020
10.1097/JTO.0b013e31826c1155
10.1016/j.lungcan.2009.11.012
10.1056/NEJMoa1200690
10.1158/1078-0432.CCR-09-3352
10.1200/JCO.2009.26.7278
10.1158/2159-8290.CD-12-0446
10.1016/j.lungcan.2011.09.011
10.1158/0008-5472.CAN-10-3590
10.1016/j.critrevonc.2011.11.010
10.1158/0008-5472.CAN-10-1671
10.1371/journal.pone.0020351
10.1038/oncsis.2013.4
10.1200/JCO.2013.50.8705
10.1038/nature06030
ContentType Journal Article
Copyright Copyright: © 2014 Shtivelman et al. 2014
Copyright_xml – notice: Copyright: © 2014 Shtivelman et al. 2014
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.18632/oncotarget.1891
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1949-2553
EndPage 1433
ExternalDocumentID PMC4039220
24722523
10_18632_oncotarget_1891
Genre Journal Article
Review
GroupedDBID ---
53G
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
FRJ
GX1
HYE
KQ8
M48
OK1
PGMZT
RPM
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c462t-6b5a0a8f38498fd6b27fcd1db13a48687a1a0c65c7d76f553d9cb70ee62f65523
IEDL.DBID M48
ISSN 1949-2553
IngestDate Thu Aug 21 18:28:32 EDT 2025
Fri Jul 11 04:34:42 EDT 2025
Thu Apr 03 07:04:50 EDT 2025
Thu Apr 24 23:08:07 EDT 2025
Tue Jul 01 01:26:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 6
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-6b5a0a8f38498fd6b27fcd1db13a48687a1a0c65c7d76f553d9cb70ee62f65523
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.18632/oncotarget.1891
PMID 24722523
PQID 1529838998
PQPubID 23479
PageCount 42
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4039220
proquest_miscellaneous_1529838998
pubmed_primary_24722523
crossref_citationtrail_10_18632_oncotarget_1891
crossref_primary_10_18632_oncotarget_1891
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-03-30
PublicationDateYYYYMMDD 2014-03-30
PublicationDate_xml – month: 03
  year: 2014
  text: 2014-03-30
  day: 30
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncotarget
PublicationTitleAlternate Oncotarget
PublicationYear 2014
Publisher Impact Journals LLC
Publisher_xml – name: Impact Journals LLC
References Stahel (70) 2013; 79
Riely (156) 2011; 29
Doebele (114) 2013
Viglietto (166) 2008; 7
Lee (41) 2007; 316
Sohara (75) 2007; 448
Leenders (130) 2013
Resh (212) 2013; 9
Latif (228) 2002; 62
Edelman (167) 2013
Niu (57) 2013
Chen (141) 2010; 69
Larson (88) 2008; 455
Ishikawa (117) 2012; 18
Janne (157) 2013
Shepherd (68) 2012; 7
Rizvi (126) 2013
Hammerman (129) 2013; 73
Heasley (50) 2013; 2
Plummer (54) 2010; 28
Markovic (226) 2011; 17
Park (55) 2012; 11
Hagiwara (13) 2009; 27
Marra (108) 2007; 7
Singh (146) 2013; 23
Hogan (214) 2011; 8
Salgia (92) 2005; 65
Balmain (203) 2013; 4
Schottle (128) 2010; 2
Gore (98) 2010; 16
Shen (125) 2012; 30
Park (163) 2010; 69
Warner (44) 2013; 19
Alberghini (238) 2005; 117
Treasure (250) 2013
Salgia (86) 2011; 3
Shokat (149) 2013; 503
Shaw (77) 2013
Reck (136) 2011; 29
Hodi (235) 2009; 15
Kurzrock (30) 2013; 4
Lawrence (132) 2011; 1
Carreno (241) 2000; 192
Lowy (244) 2013; 369
Frisen (230) 2000; 408
Shaw (36) 2013; 31
Dang (66) 2010; 69
Downward (145) 2013; 24
Fu (237) 2014; 124
Shah (24) 2013
Takahashi (174) 2000; 6
Koeffler (53) 2013; 71
Murray (144) 2008; 9
Mu (200) 2007; 104
Cohoon (7) 2013
Digumarthy (118) 2013; 368
Capelletti (42) 2010; 17
Date (78) 2010; 17
Bui (177) 2012; 13
Rabbitts (227) 2001; 98
Wetzel (115) 2007; 131
Ludlam (151) 2013
Goss (71) 2013; 31
Iafrate (139) 2007; 9
Hirsh (107) 2004; 15
Ying (61) 2012; 18
Biswal (194) 2006; 3
Brichard (251) 2013
Duffield (15) 2009; 361
Barck (215) 2013; 24
Jetten (216) 2004; 287
Reck (240) 2012; 30
Wistuba (162) 2013
Vintonyak (181) 2012; 109
Gebski (14) 2013; 105
Fakhrai (253) 2006; 24
Comoglio (87) 2006; 20
Choi (2) 2012; 150
Kelsey (164) 2005; 36
Haley (43) 2008; 25
Zha (59) 2013; 31
Wistuba (193) 2012; 7
Rosen (28) 2012; 118
Yamamoto (195) 2004; 24
Takahashi (204) 2012; 21
Yao (31) 2013; 8
Mitsudomi (91) 2009; 4
Cichowski (152) 2012
Ishihara (140) 2010; 5
Sidransky (168) 2002; 62
Padera (79) 2010; 70
Ohura (64) 2012; 69
Kaye (179) 2000; 19
Butte (231) 2013
Wei (172) 2013; 155
Romeo (121) 1994; 367
Brambilla (199) 2013; 5
Rusch (90) 2007; 104
Lorusso (96) 2013; 31
Mori (206) 2006; 15
Song (19) 2013; 14
Pardoll (234) 2012; 366
Di Renzo (93) 1996; 74
Mou (94) 2001; 32
Dong (52) 2013; 19
Yuza (56) 2010; 70
Stephens (138) 2002; 62
Yamamoto (23) 2013
72
Miller (40) 2011; 17
Sequist (12) 2013; 5
Schneider-Stock (175) 2004; 43
Kwak (76) 2009; 27
Bivona (160) 2014; 111
Ciliberto (111) 2012; 3
Gazdar (161) 2008; 68
Varmus (49) 2014
Salgia (97) 2011; 11
Mok (80) 2013; 368
Recio (158) 2013; 8
Sariola (122) 2005; 16
Ruschoff (103) 2003; 9
Miller (34) 2010; 28
Bergsagel (185) 2011; 146
Chandel (198) 2013
Sanchez-Cespedes (189) 2008; 29
Markel (239) 2012; 2012
Hirsch (9) 2004; 10
Gazdar (11) 2009; 28
Webb (63) 2013
Yang (48) 2012; 109
Maciag (148) 2014
Kato (105) 2003; 103
Waldmann (147) 2013; 497
Simon (16) 2012; 7
Lin (192) 2013
Franklin (153) 2013; 19
Broderick (201) 2007; 450
Garraway (137) 2013
Levine (8) 2013; 154
Sanchez-Cespedes (187) 2013
Clinical Lung Cancer Genome P and Network Genomic M (1) 2013; 5
Floriani (74) 2013
Heo (83) 2013; 8
Greulich (182) 2010; 463
Li (169) 2007; 448
Ball (220) 1997; 386
Liu (176) 2004; 303
Maira (170) 2010; 17
Brahmer (248) 2013; 31
Eck (39) 2008; 105
Druker (119) 2013; 110
Miyoshi (62) 2012; 76
Ferguson (89) 2009; 15
Ito (207) 2013; 24
Svane (252) 2013
Chen (243) 2010; 28
Fields (211) 2014; 25
Sun (106) 2011; 3
Morris (82) 2013; 3
Shepherd (109) 2010; 16
Meyerson (127) 2011; 6
Soria (110) 2014; 32
McCormick (113) 2013
Crino (150) 2013; 14
Ladanyi (116) 2012; 18
Rottier (208) 2008; 317
Shepherd (142) 2013; 8
Wistuba (191) 2013
Seo (123) 2012; 22
Oudejans (221) 2002; 8
White (159) 2013
Burstein (217) 2003; 119
Pao (47) 2012; 2
Xiong (3) 2012; 150
Zhang (210) 2013; 5
Shaw (173) 2013; 23
Crino (26) 2012; 78
Evan (180) 2013; 27
Marchetti (99) 2006; 119
Wong (186) 2013
Stewart (205) 2013
Haspinger (73) 2013
Chen (242) 2012; 366
Miller (22) 2012; 13
Li (190) 2013; 153
Larsen (225) 2006; 52
O'Kelly (209) 2009; 41
Bishop (184) 2011; 71
Gregorc (67) 2012; 7
Tamura (81) 2013; 14
Wistuba (196) 2010; 16
Ramirez (202) 2012; 7
Betticher (183) 1999; 79
Schiller (95) 2011; 29
Klughammer (33) 2010; 14
Harari (58) 2013; 73
Cardoso (213) 2009; 136
Hahn (51) 2011; 1
Cole (101) 2004; 431
Haber (10) 2007; 7
Alexander (197) 2013; 2013
Schildhaus (5) 2012; 44
Hammerman (133) 2013; 8
Baylin (224) 2003; 422
Meyerson (155) 2002; 62
Ball (222) 2004; 14
Gazdar (100) 2005; 65
Cancer Genome Atlas Research N (4) 2012; 489
Johnson (21) 2013; 6
Bhardwaj (6) 2012; 2
Sidransky (218) 2000; 97
Sun (32) 2013; 14
Ellisen (219) 2013
Wolchok (246) 2013; 1
Hegmans (233) 2013; 73
Antonia (247) 2007; 25
Okayama (124) 2012; 18
Driggers (171) 2013
Ball (223) 2001; 61
Wolchok (236) 2013; 19
Ou (20) 2012; 83
Vecchio (120) 1987; 328
Camidge (84) 2012; 18
Janne (35) 2013; 19
Sculier (143) 2005; 92
Engelman (37) 2013; 6
Gualberto (135) 2009; 27
Thomas (104) 2005; 48
Andersson (178) 2012; 30
Hirsch (29) 2012; 30
O'Connell (25) 2012; 30
Carbone (69) 2010; 5
Chen (18) 2011; 12
Menendez (45) 2013; 3
Byers (232) 2013
Rabbitts (229) 2004; 64
Shaw (85) 2011; 108
Ji (131) 2012; 18
investigators (65) 2010; 11
Cooper (154) 1990; 247
Kalaany (165) 2013
Slamon (60) 2013
Ogura (17) 2010; 362
Varmus (38) 2005; 2
Felip (102) 2013
Ciliberto (112) 2013
Herman (188) 2008; 358
Tykodi (245) 2013; 4
Vansteenkiste (249) 2012; 23
Meyerson (27) 2005; 2
Downward (134) 2013; 3
Lynch (46) 2011; 3
References_xml – volume: 6
  start-page: 4055
  issue: 10
  year: 2000
  ident: 174
  article-title: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 79
  start-page: 952
  year: 1999
  ident: 183
  article-title: Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer
  publication-title: British journal of cancer
  doi: 10.1038/sj.bjc.6690152
– year: 2013
  ident: 205
  article-title: Wnt Signaling Pathway in Non-Small Cell Lung Cancer
  publication-title: Journal of the National Cancer Institute
– volume: 24
  start-page: 7130
  issue: 16
  year: 2004
  ident: 195
  article-title: Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2
  publication-title: Molecular and cellular biology
  doi: 10.1128/MCB.24.16.7130-7139.2004
– volume: 2
  start-page: e73
  issue: 3
  year: 2005
  ident: 38
  article-title: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
  publication-title: PLoS medicine
  doi: 10.1371/journal.pmed.0020073
– volume: 41
  start-page: 1238
  issue: 11
  year: 2009
  ident: 209
  article-title: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
  publication-title: Nature genetics
  doi: 10.1038/ng.465
– volume: 64
  start-page: 6432
  issue: 18
  year: 2004
  ident: 229
  article-title: Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-04-2561
– volume: 497
  start-page: 638
  issue: 7451
  year: 2013
  ident: 147
  article-title: Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling
  publication-title: Nature
  doi: 10.1038/nature12205
– volume: 22
  start-page: 436
  issue: 3
  year: 2012
  ident: 123
  article-title: A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
  publication-title: Genome research
  doi: 10.1101/gr.133645.111
– volume: 2
  start-page: e313
  issue: 11
  year: 2005
  ident: 27
  article-title: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
  publication-title: PLoS medicine
  doi: 10.1371/journal.pmed.0020313
– volume: 52
  start-page: 281
  issue: 3
  year: 2006
  ident: 225
  article-title: Hedgehog signaling in small-cell lung cancer: frequentbut a rare event
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2005.12.014
– volume: 105
  start-page: 595
  issue: 9
  year: 2013
  ident: 14
  article-title: Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
  publication-title: Journal of the National Cancer Institute
  doi: 10.1093/jnci/djt072
– volume: 48
  start-page: 59
  issue: 1
  year: 2005
  ident: 104
  article-title: HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2004.10.010
– volume: 24
  start-page: 59
  issue: 1
  year: 2013
  ident: 215
  article-title: A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2013.05.021
– volume: 8
  start-page: 415
  issue: 4
  year: 2013
  ident: 83
  article-title: Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e318283dcc0
– volume: 8
  start-page: 530
  issue: 5
  year: 2013
  ident: 142
  article-title: KRAS mutations as prognostic and predictive markers in non-small cell lung cancer
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e318283d958
– year: 2014
  ident: 49
  article-title: Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
  publication-title: Cancer discovery
– year: 2013
  ident: 231
  article-title: A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
  publication-title: Cancer discovery
– volume: 1
  start-page: 78
  issue: 1
  year: 2011
  ident: 132
  article-title: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
  publication-title: Cancer discovery
  doi: 10.1158/2159-8274.CD-11-0005
– volume: 8
  start-page: 1082
  issue: 4
  year: 2002
  ident: 221
  article-title: Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 5
  start-page: 209ra153
  issue: 209
  year: 2013
  ident: 1
  article-title: A genomics-based classification of human lung tumors
  publication-title: Science translational medicine
– volume: 3
  start-page: 75ra26
  issue: 75
  year: 2011
  ident: 46
  article-title: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
  publication-title: Science translational medicine
– volume: 74
  start-page: 1862
  issue: 12
  year: 1996
  ident: 93
  article-title: Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas
  publication-title: British journal of cancer
  doi: 10.1038/bjc.1996.646
– year: 2013
  ident: 198
  article-title: Targeting SOD1 reduces experimental non-small-cell lung cancer
  publication-title: The Journal of clinical investigation
– volume: 31
  start-page: 742
  issue: 3
  year: 2013
  ident: 96
  article-title: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
  publication-title: Investigational new drugs
  doi: 10.1007/s10637-012-9881-z
– volume: 78
  start-page: 81
  issue: 1
  year: 2012
  ident: 26
  article-title: Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2012.06.005
– volume: 14
  start-page: 51
  year: 2010
  ident: 33
  article-title: Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
  publication-title: Journal of cellular and molecular medicine
  doi: 10.1111/j.1582-4934.2009.00991.x
– volume: 15
  start-page: 129
  issue: 1
  year: 2006
  ident: 206
  article-title: Epigenetic inactivation of the RUNX3 gene in lung cancer
  publication-title: Oncology reports
– volume: 109
  start-page: 17034
  issue: 42
  year: 2012
  ident: 181
  article-title: A framework for identification of actionable cancer genome dependencies in small cell lung cancer
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.1207310109
– volume: 2
  start-page: 798
  issue: 9
  year: 2012
  ident: 6
  article-title: Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1
  publication-title: Cancer discovery
  doi: 10.1158/2159-8290.CD-12-0112
– volume: 69
  start-page: 337
  issue: 3
  year: 2010
  ident: 66
  article-title: VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2009.11.019
– volume: 19
  start-page: 1389
  issue: 11
  year: 2013
  ident: 35
  article-title: The quest to overcome resistance to EGFR-targeted therapies in cancer
  publication-title: Nature medicine
  doi: 10.1038/nm.3388
– volume: 20
  start-page: 1611
  issue: 10
  year: 2006
  ident: 87
  article-title: The Met pathway: master switch and drug target in cancer progression
  publication-title: FASEB journal: official publication of the Federation of American Societies for Experimental Biology
  doi: 10.1096/fj.06-5947rev
– volume: 11
  start-page: 1655
  issue: 12
  year: 2011
  ident: 97
  article-title: Role of MetMAb (OA-5D5) in c-MET active lung malignancies
  publication-title: Expert opinion on biological therapy
  doi: 10.1517/14712598.2011.626762
– volume: 153
  start-page: 590
  issue: 3
  year: 2013
  ident: 190
  article-title: The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSalpha
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.025
– year: 2013
  ident: 251
  article-title: Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
– volume: 25
  start-page: 139
  issue: 2
  year: 2014
  ident: 211
  article-title: The PRKCI and SOX2 Oncogenes Are Coamplified and Cooperate to Activate Hedgehog Signaling in Lung Squamous Cell Carcinoma
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2014.01.008
– volume: 69
  start-page: 1241
  issue: 5
  year: 2012
  ident: 64
  article-title: A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
  publication-title: Cancer chemotherapy and pharmacology
  doi: 10.1007/s00280-012-1831-0
– volume: 124
  start-page: 687
  issue: 2
  year: 2014
  ident: 237
  article-title: Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
  publication-title: The Journal of clinical investigation
  doi: 10.1172/JCI67313
– volume: 25
  start-page: 876
  issue: 7
  year: 2007
  ident: 247
  article-title: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2006.08.3311
– volume: 12
  start-page: 735
  issue: 8
  year: 2011
  ident: 18
  article-title: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(11)70184-X
– year: 2013
  ident: 60
  article-title: The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth
  publication-title: Molecular cancer therapeutics
– volume: 32
  start-page: 57
  issue: 1
  year: 2001
  ident: 94
  article-title: Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer
  publication-title: Human pathology
  doi: 10.1053/hupa.2001.21133
– volume: 61
  start-page: 3200
  issue: 7
  year: 2001
  ident: 223
  article-title: Notch signaling induces cell cycle arrest in small cell lung cancer cells
  publication-title: Cancer research
– volume: 11
  start-page: 521
  issue: 6
  year: 2010
  ident: 65
  article-title: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(10)70112-1
– volume: 7
  start-page: S342
  issue: 16 Suppl 5
  year: 2012
  ident: 16
  article-title: A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
– volume: 7
  start-page: e29907
  issue: 1
  year: 2012
  ident: 202
  article-title: Genome-wide analyses of Nkx2-1 binding to transcriptional target genes uncover novel regulatory patterns conserved in lung development and tumors
  publication-title: PloS one
  doi: 10.1371/journal.pone.0029907
– volume: 29
  start-page: 617
  issue: 5
  year: 2008
  ident: 189
  article-title: Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines
  publication-title: Human mutation
  doi: 10.1002/humu.20730
– volume: 98
  start-page: 15062
  issue: 26
  year: 2001
  ident: 227
  article-title: Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.251407098
– volume: 25
  start-page: 843
  issue: 8
  year: 2008
  ident: 43
  article-title: Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
  publication-title: Clinical & experimental metastasis
  doi: 10.1007/s10585-008-9200-4
– volume: 4
  start-page: 2067
  issue: 11
  year: 2013
  ident: 245
  article-title: Alterations of immune response of non-small cell lung cancer with Azacytidine
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.1542
– volume: 16
  start-page: 1938
  issue: 6
  year: 2010
  ident: 109
  article-title: Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-08-3328
– year: 2013
  ident: 171
  article-title: Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer
  publication-title: Cancer discovery
– volume: 1
  start-page: 608
  issue: 7
  year: 2011
  ident: 51
  article-title: Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers
  publication-title: Cancer discovery
  doi: 10.1158/2159-8290.CD-11-0046
– volume: 92
  start-page: 131
  issue: 1
  year: 2005
  ident: 143
  article-title: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
  publication-title: British journal of cancer
  doi: 10.1038/sj.bjc.6602258
– volume: 73
  start-page: 2381
  issue: 8
  year: 2013
  ident: 233
  article-title: Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-12-3932
– volume: 4
  start-page: 1701
  year: 2013
  ident: 203
  article-title: Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas
  publication-title: Nature communications
  doi: 10.1038/ncomms2660
– volume: 62
  start-page: 6997
  issue: 23
  year: 2002
  ident: 138
  article-title: BRAF and RAS mutations in human lung cancer and melanoma
  publication-title: Cancer research
– volume: 19
  start-page: 3894
  issue: 14
  year: 2013
  ident: 52
  article-title: USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-12-3696
– volume: 29
  start-page: 2046
  issue: 15
  year: 2011
  ident: 156
  article-title: Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2010.33.1280
– volume: 2
  start-page: 922
  issue: 10
  year: 2012
  ident: 47
  article-title: HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
  publication-title: Cancer discovery
  doi: 10.1158/2159-8290.CD-12-0108
– volume: 4
  start-page: 5
  issue: 1
  year: 2009
  ident: 91
  article-title: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e3181913e0e
– year: 2013
  ident: 219
  article-title: FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma
  publication-title: The Journal of clinical investigation
– volume: 68
  start-page: 6913
  issue: 17
  year: 2008
  ident: 161
  article-title: PIK3CA mutations and copy number gains in human lung cancers
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-07-5084
– volume: 31
  start-page: 4105
  issue: 32
  year: 2013
  ident: 59
  article-title: Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2012.47.4189
– volume: 105
  start-page: 2070
  issue: 6
  year: 2008
  ident: 39
  article-title: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.0709662105
– volume: 150
  start-page: 1121
  issue: 6
  year: 2012
  ident: 3
  article-title: Genomic landscape of non-small cell lung cancer in smokers and never-smokers
  publication-title: Cell
  doi: 10.1016/j.cell.2012.08.024
– volume: 450
  start-page: 893
  issue: 7171
  year: 2007
  ident: 201
  article-title: Characterizing the cancer genome in lung adenocarcinoma
  publication-title: Nature
  doi: 10.1038/nature06358
– volume: 43
  start-page: 285
  issue: 3
  year: 2004
  ident: 175
  article-title: MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2003.09.010
– volume: 1
  issue: 5
  year: 2013
  ident: 246
  article-title: GITR Pathway Activation Abrogates Tumor Immune Suppression Through Loss of Regulatory T cell Lineage Stability
  publication-title: Cancer immunology research
– volume: 111
  start-page: E748
  issue: 7
  year: 2014
  ident: 160
  article-title: Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
  publication-title: Proceedings of the National Academy of Sciences
  doi: 10.1073/pnas.1320956111
– volume: 368
  start-page: 2385
  issue: 25
  year: 2013
  ident: 80
  article-title: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1214886
– volume: 17
  start-page: 547
  issue: 6
  year: 2010
  ident: 170
  article-title: Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2010.04.026
– volume: 5
  start-page: 186ra166
  issue: 186
  year: 2013
  ident: 199
  article-title: Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers
  publication-title: Science translational medicine
– volume: 131
  start-page: 1190
  issue: 6
  year: 2007
  ident: 115
  article-title: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2007.11.025
– volume: 30
  start-page: 2248
  issue: 18
  year: 2012
  ident: 29
  article-title: Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2011.38.9411
– volume: 29
  start-page: 3307
  issue: 24
  year: 2011
  ident: 95
  article-title: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2010.34.0570
– volume: 19
  start-page: 279
  issue: 1
  year: 2013
  ident: 44
  article-title: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-12-1558
– volume: 17
  start-page: 1504
  issue: 11
  year: 2011
  ident: 226
  article-title: A crucial requirement for Hedgehog signaling in small cell lung cancer
  publication-title: Nature medicine
  doi: 10.1038/nm.2473
– volume: 17
  start-page: 77
  issue: 1
  year: 2010
  ident: 42
  article-title: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2009.11.022
– volume: 358
  start-page: 1118
  issue: 11
  year: 2008
  ident: 188
  article-title: DNA methylation markers and early recurrence in stage I lung cancer
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa0706550
– volume: 287
  start-page: C171
  issue: 1
  year: 2004
  ident: 216
  article-title: Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium
  publication-title: American journal of physiology Cell physiology
  doi: 10.1152/ajpcell.00226.2003
– volume: 7
  start-page: 40
  issue: 1
  year: 2012
  ident: 67
  article-title: Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e3182307f17
– volume: 9
  start-page: 5238
  issue: 14
  year: 2003
  ident: 103
  article-title: HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– year: 2013
  ident: 186
  article-title: Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 24
  start-page: 4721
  issue: 29
  year: 2006
  ident: 253
  article-title: Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2005.05.5335
– volume: 31
  start-page: 1061
  issue: 8
  year: 2013
  ident: 71
  article-title: Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2012.43.4522
– volume: 73
  start-page: 824
  issue: 2
  year: 2013
  ident: 58
  article-title: Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-12-1611
– volume: 5
  start-page: 445
  issue: 2
  year: 2013
  ident: 210
  article-title: Pluripotent Stem Cell Protein Sox2 Confers Sensitivity to LSD1 Inhibition in Cancer Cells
  publication-title: Cell reports
  doi: 10.1016/j.celrep.2013.09.018
– volume: 104
  start-page: 20932
  issue: 52
  year: 2007
  ident: 90
  article-title: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.0710370104
– year: 2013
  ident: 151
  article-title: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
  publication-title: Nature
– volume: 97
  start-page: 5462
  issue: 10
  year: 2000
  ident: 218
  article-title: AIS is an oncogene amplified in squamous cell carcinoma
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.97.10.5462
– volume: 316
  start-page: 1039
  issue: 5827
  year: 2007
  ident: 41
  article-title: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
  publication-title: Science
  doi: 10.1126/science.1141478
– volume: 408
  start-page: 203
  issue: 6809
  year: 2000
  ident: 230
  article-title: Regulation of repulsion versus adhesion by different splice forms of an Eph receptor
  publication-title: Nature
  doi: 10.1038/35041577
– year: 2013
  ident: 112
  article-title: Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
  publication-title: Oncotarget
– volume: 24
  start-page: 617
  issue: 5
  year: 2013
  ident: 145
  article-title: Requirement for Interaction of PI3-Kinase p110alpha with RAS in Lung Tumor Maintenance
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2013.09.012
– volume: 431
  start-page: 525
  issue: 7008
  year: 2004
  ident: 101
  article-title: Lung cancer: intragenic ERBB2 kinase mutations in tumours
  publication-title: Nature
  doi: 10.1038/431525b
– volume: 247
  start-page: 1578
  issue: 4950
  year: 1990
  ident: 154
  article-title: Binding of GAP to activated PDGF receptors
  publication-title: Science
  doi: 10.1126/science.2157284
– volume: 4
  start-page: 118
  issue: 1
  year: 2013
  ident: 30
  article-title: Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.763
– volume: 362
  start-page: 2380
  issue: 25
  year: 2010
  ident: 17
  article-title: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa0909530
– volume: 14
  start-page: 357
  issue: 5
  year: 2004
  ident: 222
  article-title: Notch in lung development and lung cancer
  publication-title: Seminars in cancer biology
  doi: 10.1016/j.semcancer.2004.04.015
– year: 2013
  ident: 130
  article-title: Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer
  publication-title: Cancer discovery
– volume: 155
  start-page: 552
  issue: 3
  year: 2013
  ident: 172
  article-title: Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2013.09.041
– volume: 2012
  start-page: 818214
  year: 2012
  ident: 239
  article-title: Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms
  publication-title: Clinical & developmental immunology
– volume: 79
  start-page: 59
  issue: 1
  year: 2013
  ident: 70
  article-title: VeriStrat(R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2012.10.006
– volume: 31
  start-page: 1021
  issue: 8
  year: 2013
  ident: 248
  article-title: Harnessing the immune system for the treatment of non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2012.45.8703
– volume: 366
  start-page: 2455
  issue: 26
  year: 2012
  ident: 242
  article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1200694
– volume: 62
  start-page: 5874
  issue: 20
  year: 2002
  ident: 228
  article-title: SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers
  publication-title: Cancer research
– volume: 5
  start-page: 169
  issue: 2
  year: 2010
  ident: 69
  article-title: Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/01243894-200602000-00012
– volume: 328
  start-page: 170
  issue: 6126
  year: 1987
  ident: 120
  article-title: A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases
  publication-title: Nature
  doi: 10.1038/328170a0
– volume: 62
  start-page: 7001
  issue: 23
  year: 2002
  ident: 155
  article-title: Missense mutations of the BRAF gene in human lung adenocarcinoma
  publication-title: Cancer research
– year: 2012
  ident: 152
  article-title: Elucidating distinct roles for NF1 in melanomagenesis
  publication-title: Cancer discovery
– volume: 118
  start-page: 5903
  issue: 23
  year: 2012
  ident: 28
  article-title: Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
  publication-title: Cancer
  doi: 10.1002/cncr.27575
– volume: 27
  start-page: 1394
  issue: 9
  year: 2009
  ident: 13
  article-title: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2008.18.7658
– volume: 18
  start-page: 378
  issue: 3
  year: 2012
  ident: 117
  article-title: RET, ROS1 and ALK fusions in lung cancer
  publication-title: Nature medicine
  doi: 10.1038/nm.2658
– volume: 29
  start-page: 4574
  issue: 34
  year: 2011
  ident: 136
  article-title: Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2011.36.6799
– volume: 8
  start-page: 1434
  issue: 11
  year: 2013
  ident: 133
  article-title: Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e3182a47162
– volume: 30
  start-page: 3633
  issue: 29
  year: 2012
  ident: 178
  article-title: Targeting p53: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2011.40.7783
– year: 2013
  ident: 74
  article-title: Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
  publication-title: The lancet oncology
– volume: 119
  start-page: 696
  issue: 5
  year: 2003
  ident: 217
  article-title: p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung
  publication-title: American journal of clinical pathology
  doi: 10.1309/P5ABR5KQ89RNJTFH
– volume: 31
  start-page: 3987
  issue: 31
  year: 2013
  ident: 36
  article-title: Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2012.45.2029
– volume: 15
  start-page: 19
  issue: 1
  year: 2004
  ident: 107
  article-title: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
  publication-title: Annals of oncology: official journal of the European Society for Medical Oncology / ESMO
  doi: 10.1093/annonc/mdh031
– volume: 136
  start-page: 2297
  issue: 13
  year: 2009
  ident: 213
  article-title: Notch signaling controls the balance of ciliated and secretory cell fates in developing airways
  publication-title: Development
  doi: 10.1242/dev.034884
– year: 2013
  ident: 165
  article-title: Pten-Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction
  publication-title: Cancer discovery
– volume: 9
  start-page: 247
  issue: 4
  year: 2013
  ident: 212
  article-title: Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling
  publication-title: Nature chemical biology
  doi: 10.1038/nchembio.1184
– volume: 19
  start-page: 2584
  issue: 9
  year: 2013
  ident: 153
  article-title: Characteristics of Lung Cancers Harboring NRAS Mutations
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-12-3173
– volume: 65
  start-page: 1642
  issue: 5
  year: 2005
  ident: 100
  article-title: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-04-4235
– volume: 8
  start-page: e66933
  issue: 6
  year: 2013
  ident: 158
  article-title: Lkb1 Loss Promotes Tumor Progression of BRAF(V600E)-Induced Lung Adenomas
  publication-title: PloS one
  doi: 10.1371/journal.pone.0066933
– year: 2013
  ident: 73
  article-title: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non-Small-Cell Lung Cancer: The Never-Ending Story
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
– volume: 150
  start-page: 1107
  issue: 6
  year: 2012
  ident: 2
  article-title: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
  publication-title: Cell
  doi: 10.1016/j.cell.2012.08.029
– volume: 28
  start-page: 3167
  issue: 19
  year: 2010
  ident: 243
  article-title: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2009.26.7609
– year: 2013
  ident: 23
  article-title: LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
– volume: 17
  start-page: 1616
  issue: 6
  year: 2011
  ident: 40
  article-title: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-10-2692
– volume: 5
  start-page: 1197
  issue: 8
  year: 2010
  ident: 140
  article-title: Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e3181e2a2bc
– volume: 503
  start-page: 548
  issue: 7477
  year: 2013
  ident: 149
  article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
  publication-title: Nature
  doi: 10.1038/nature12796
– volume: 10
  start-page: 4227s
  issue: 12 Pt 2
  year: 2004
  ident: 9
  article-title: The biology of epidermal growth factor receptor in lung cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 448
  start-page: 561
  issue: 7153
  year: 2007
  ident: 75
  article-title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
  publication-title: Nature
  doi: 10.1038/nature05945
– volume: 3
  start-page: 171
  issue: 4
  year: 2011
  ident: 86
  article-title: The role of the c-Met pathway in lung cancer and the potential for targeted therapy
  publication-title: Therapeutic advances in medical oncology
  doi: 10.1177/1758834011408636
– volume: 24
  start-page: 603
  issue: 5
  year: 2013
  ident: 207
  article-title: Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2013.10.003
– volume: 14
  start-page: 777
  issue: 8
  year: 2013
  ident: 32
  article-title: Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(13)70254-7
– volume: 73
  start-page: 5195
  issue: 16
  year: 2013
  ident: 129
  article-title: Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-12-3950
– year: 2013
  ident: 192
  article-title: KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling
  publication-title: The Journal of clinical investigation
– year: 2013
  ident: 57
  article-title: Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
  publication-title: Cancer discovery
– volume: 17
  start-page: 889
  issue: 3
  year: 2010
  ident: 78
  article-title: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene
  publication-title: Annals of surgical oncology
  doi: 10.1245/s10434-009-0808-7
– volume: 361
  start-page: 947
  issue: 10
  year: 2009
  ident: 15
  article-title: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa0810699
– volume: 108
  start-page: 7535
  issue: 18
  year: 2011
  ident: 85
  article-title: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.1019559108
– volume: 27
  start-page: 504
  issue: 5
  year: 2013
  ident: 180
  article-title: Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
  publication-title: Genes & development
  doi: 10.1101/gad.205542.112
– volume: 13
  start-page: 539
  issue: 5
  year: 2012
  ident: 22
  article-title: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(12)70086-4
– volume: 15
  start-page: 5714
  issue: 18
  year: 2009
  ident: 89
  article-title: Ethnic differences and functional analysis of MET mutations in lung cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-09-0070
– year: 2013
  ident: 7
  article-title: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
  publication-title: Cancer discovery
– volume: 192
  start-page: 1027
  issue: 7
  year: 2000
  ident: 241
  article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
  publication-title: The Journal of experimental medicine
  doi: 10.1084/jem.192.7.1027
– volume: 23
  start-page: 1387
  issue: 6
  year: 2012
  ident: 249
  article-title: Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
  publication-title: Annals of oncology: official journal of the European Society for Medical Oncology / ESMO
  doi: 10.1093/annonc/mdr564
– volume: 65
  start-page: 1479
  issue: 4
  year: 2005
  ident: 92
  article-title: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-04-2650
– volume: 23
  start-page: 143
  issue: 2
  year: 2013
  ident: 173
  article-title: LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2012.12.008
– volume: 21
  start-page: 348
  issue: 3
  year: 2012
  ident: 204
  article-title: NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2012.02.008
– volume: 8
  start-page: e55637
  issue: 2
  year: 2013
  ident: 31
  article-title: Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data
  publication-title: PloS one
  doi: 10.1371/journal.pone.0055637
– volume: 7
  start-page: 128
  year: 2007
  ident: 108
  article-title: Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
  publication-title: BMC cancer
  doi: 10.1186/1471-2407-7-128
– volume: 27
  start-page: 4247
  issue: 26
  year: 2009
  ident: 76
  article-title: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2009.22.6993
– volume: 6
  start-page: re6
  issue: 294
  year: 2013
  ident: 37
  article-title: Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer
  publication-title: Science signaling
– volume: 14
  start-page: 38
  issue: 1
  year: 2013
  ident: 150
  article-title: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(12)70489-8
– volume: 455
  start-page: 1069
  issue: 7216
  year: 2008
  ident: 88
  article-title: Somatic mutations affect key pathways in lung adenocarcinoma
  publication-title: Nature
  doi: 10.1038/nature07423
– volume: 7
  start-page: 665
  issue: 5
  year: 2008
  ident: 166
  article-title: Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung
  publication-title: Cell cycle
  doi: 10.4161/cc.7.5.5485
– volume: 9
  start-page: 320
  issue: 3
  year: 2007
  ident: 139
  article-title: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features
  publication-title: The Journal of molecular diagnostics: JMD
  doi: 10.2353/jmoldx.2007.060182
– year: 2013
  ident: 187
  article-title: MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1
  publication-title: Cancer discovery
– volume: 109
  start-page: E2127
  issue: 31
  year: 2012
  ident: 48
  article-title: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.1203530109
– volume: 30
  start-page: 2046
  issue: 17
  year: 2012
  ident: 240
  article-title: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2011.38.4032
– year: 2013
  ident: 252
  article-title: Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 18
  start-page: 6599
  issue: 24
  year: 2012
  ident: 116
  article-title: Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-12-0838
– year: 2013
  ident: 159
  article-title: Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of BrafV600E-Driven Lung Tumors
  publication-title: Cancer discovery
– volume: 30
  start-page: 3337
  issue: 27
  year: 2012
  ident: 25
  article-title: Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2011.40.9433
– volume: 16
  start-page: 441
  year: 2005
  ident: 122
  article-title: RET tyrosine kinase signaling in development and cancer
  publication-title: Cytokine & growth factor reviews
  doi: 10.1016/j.cytogfr.2005.05.010
– volume: 18
  start-page: 1472
  issue: 5
  year: 2012
  ident: 84
  article-title: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-11-2906
– year: 2013
  ident: 114
  article-title: Molecular Pathways: ROS1 Fusion Proteins in Cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 146
  start-page: 904
  issue: 6
  year: 2011
  ident: 185
  article-title: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
  publication-title: Cell
  doi: 10.1016/j.cell.2011.08.017
– volume: 368
  start-page: 2395
  issue: 25
  year: 2013
  ident: 118
  article-title: Acquired resistance to crizotinib from a mutation in CD74-ROS1
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1215530
– volume: 8
  start-page: 639
  issue: 6
  year: 2011
  ident: 214
  article-title: Notch-dependent differentiation of adult airway basal stem cells
  publication-title: Cell stem cell
  doi: 10.1016/j.stem.2011.04.003
– volume: 19
  start-page: 1009
  issue: 5
  year: 2013
  ident: 236
  article-title: Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-12-2982
– volume: 489
  start-page: 519
  issue: 7417
  year: 2012
  ident: 4
  article-title: Comprehensive genomic characterization of squamous cell lung cancers
  publication-title: Nature
  doi: 10.1038/nature11404
– volume: 367
  start-page: 375
  issue: 6461
  year: 1994
  ident: 121
  article-title: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
  publication-title: Nature
  doi: 10.1038/367375a0
– volume: 18
  start-page: 375
  issue: 3
  year: 2012
  ident: 124
  article-title: KIF5B-RET fusions in lung adenocarcinoma
  publication-title: Nature medicine
  doi: 10.1038/nm.2644
– volume: 11
  start-page: 784
  issue: 3
  year: 2012
  ident: 55
  article-title: The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor
  publication-title: Molecular cancer therapeutics
  doi: 10.1158/1535-7163.MCT-11-0750
– volume: 28
  start-page: S24
  issue: Suppl 1
  year: 2009
  ident: 11
  article-title: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
  publication-title: Oncogene
  doi: 10.1038/onc.2009.198
– volume: 19
  start-page: 4632
  issue: 40
  year: 2000
  ident: 179
  article-title: Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1203815
– volume: 44
  start-page: 1104
  issue: 10
  year: 2012
  ident: 5
  article-title: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
  publication-title: Nature genetics
  doi: 10.1038/ng.2396
– year: 2013
  ident: 63
  article-title: A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 119
  start-page: 2586
  issue: 11
  year: 2006
  ident: 99
  article-title: Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features
  publication-title: International journal of cancer Journal international du cancer
  doi: 10.1002/ijc.22143
– volume: 3
  start-page: 2560
  year: 2013
  ident: 45
  article-title: IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
  publication-title: Scientific reports
  doi: 10.1038/srep02560
– volume: 16
  start-page: 699
  issue: 2
  year: 2010
  ident: 98
  article-title: Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-09-1365
– volume: 3
  start-page: e420
  issue: 10
  year: 2006
  ident: 194
  article-title: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer
  publication-title: PLoS medicine
  doi: 10.1371/journal.pmed.0030420
– volume: 30
  start-page: 4352
  issue: 35
  year: 2012
  ident: 125
  article-title: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2012.44.1477
– year: 2013
  ident: 137
  article-title: Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
  publication-title: Nature medicine
– volume: 303
  start-page: 844
  issue: 5659
  year: 2004
  ident: 176
  article-title: activation of the p53 pathway by small-molecule antagonists of MDM2
  publication-title: Science
  doi: 10.1126/science.1092472
– volume: 422
  start-page: 313
  issue: 6929
  year: 2003
  ident: 224
  article-title: Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
  publication-title: Nature
  doi: 10.1038/nature01493
– volume: 154
  start-page: 1269
  issue: 6
  year: 2013
  ident: 8
  article-title: EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance
  publication-title: Cell
  doi: 10.1016/j.cell.2013.08.015
– volume: 3
  start-page: 430
  issue: 4
  year: 2013
  ident: 82
  article-title: Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
  publication-title: Cancer discovery
  doi: 10.1158/2159-8290.CD-12-0440
– year: 2013
  ident: 102
  article-title: Lung Cancer That Harbors a HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
– volume: 7
  start-page: e37775
  issue: 5
  year: 2012
  ident: 193
  article-title: Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development
  publication-title: PloS one
  doi: 10.1371/journal.pone.0037775
– volume: 104
  start-page: 16663
  issue: 42
  year: 2007
  ident: 200
  article-title: Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.0708286104
– volume: 70
  start-page: 868
  issue: 3
  year: 2010
  ident: 56
  article-title: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-09-3106
– volume: 27
  start-page: 2516
  issue: 15
  year: 2009
  ident: 135
  article-title: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2008.19.9331
– volume: 110
  start-page: 19519
  issue: 48
  year: 2013
  ident: 119
  article-title: Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.1319583110
– volume: 2
  start-page: 62ra93
  issue: 62
  year: 2010
  ident: 128
  article-title: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
  publication-title: Science translational medicine
– volume: 36
  start-page: 768
  issue: 7
  year: 2005
  ident: 164
  article-title: PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration
  publication-title: Human pathology
  doi: 10.1016/j.humpath.2005.05.006
– volume: 13
  start-page: 1133
  issue: 11
  year: 2012
  ident: 177
  article-title: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(12)70474-6
– volume: 2013
  start-page: 746432
  year: 2013
  ident: 197
  article-title: The involvement of NRF2 in lung cancer
  publication-title: Oxidative medicine and cellular longevity
– volume: 32
  start-page: 68
  issue: 2
  year: 2014
  ident: 110
  article-title: Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2012.47.2787
– volume: 14
  start-page: 590
  issue: 7
  year: 2013
  ident: 81
  article-title: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(13)70142-6
– volume: 9
  start-page: 962
  issue: 10
  year: 2008
  ident: 144
  article-title: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(08)70206-7
– volume: 15
  start-page: 7412
  issue: 23
  year: 2009
  ident: 235
  article-title: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-09-1624
– year: 2013
  ident: 24
  article-title: Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
– volume: 28
  start-page: 357
  issue: 2
  year: 2010
  ident: 34
  article-title: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2009.24.7049
– volume: 103
  start-page: 61
  issue: 1
  year: 2003
  ident: 105
  article-title: Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer
  publication-title: International journal of cancer Journal international du cancer
  doi: 10.1002/ijc.10795
– volume: 369
  start-page: 122
  issue: 2
  year: 2013
  ident: 244
  article-title: Nivolumab plus ipilimumab in advanced melanoma
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1302369
– volume: 6
  start-page: 135
  year: 2013
  ident: 21
  article-title: Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
  publication-title: OncoTargets and therapy
– year: 2013
  ident: 191
  article-title: EZH2 Protein Expression Associates With the Early Pathogenesis, Tumor Progression and Prognosis of Non-small Cell Lung Carcinoma
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– year: 2013
  ident: 232
  article-title: Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 14
  start-page: 953
  issue: 10
  year: 2013
  ident: 19
  article-title: Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
  publication-title: The lancet oncology
  doi: 10.1016/S1470-2045(13)70355-3
– volume: 7
  start-page: 169
  issue: 3
  year: 2007
  ident: 10
  article-title: Epidermal growth factor receptor mutations in lung cancer
  publication-title: Nature reviews Cancer
  doi: 10.1038/nrc2088
– year: 2013
  ident: 250
  article-title: Adjuvant MAGE-A3 Immunotherapy in Resected Non-Small-Cell Lung Cancer: Phase II Randomized Study Results
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
– volume: 463
  start-page: 899
  issue: 7283
  year: 2010
  ident: 182
  article-title: The landscape of somatic copy-number alteration across human cancers
  publication-title: Nature
  doi: 10.1038/nature08822
– volume: 386
  start-page: 852
  issue: 6627
  year: 1997
  ident: 220
  article-title: An achaete-scute homologue essential for neuroendocrine differentiation in the lung
  publication-title: Nature
  doi: 10.1038/386852a0
– year: 2013
  ident: 126
  article-title: Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
  publication-title: Cancer discovery
– volume: 117
  start-page: 538
  issue: 4
  year: 2005
  ident: 238
  article-title: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
  publication-title: International journal of cancer Journal international du cancer
  doi: 10.1002/ijc.21155
– volume: 5
  start-page: 216ra177
  issue: 216
  year: 2013
  ident: 12
  article-title: Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
  publication-title: Science translational medicine
  doi: 10.1126/scitranslmed.3007205
– volume: 18
  start-page: 4973
  issue: 18
  year: 2012
  ident: 61
  article-title: Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity inandmodels of non-small cell lung cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-11-2967
– volume: 18
  start-page: 6658
  issue: 24
  year: 2012
  ident: 131
  article-title: Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-12-2694
– volume: 23
  start-page: 121
  issue: 1
  year: 2013
  ident: 146
  article-title: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
  publication-title: Cancer cell
  doi: 10.1016/j.ccr.2012.11.007
– volume: 317
  start-page: 296
  issue: 1
  year: 2008
  ident: 208
  article-title: Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation
  publication-title: Developmental biology
  doi: 10.1016/j.ydbio.2008.02.035
– volume: 71
  start-page: 1325
  issue: 5
  year: 2013
  ident: 53
  article-title: Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
  publication-title: Cancer chemotherapy and pharmacology
  doi: 10.1007/s00280-013-2132-y
– volume: 3
  start-page: 744
  issue: 8
  year: 2012
  ident: 111
  article-title: The promise of anti-ErbB3 monoclonals as new cancer therapeutics
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.550
– volume: 69
  start-page: 272
  issue: 3
  year: 2010
  ident: 141
  article-title: KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2009.11.020
– volume: 7
  start-page: 1653
  issue: 11
  year: 2012
  ident: 68
  article-title: Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial
  publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
  doi: 10.1097/JTO.0b013e31826c1155
– volume: 3
  start-page: 99ra86
  issue: 99
  year: 2011
  ident: 106
  article-title: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
  publication-title: Science translational medicine
– volume: 69
  start-page: 279
  issue: 3
  year: 2010
  ident: 163
  article-title: PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2009.11.012
– year: 2013
  ident: 77
  article-title: ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– year: 2013
  ident: 167
  article-title: Phase I safety, pharmacokinetic and pharmacodynamic study of SAR245408 (XL147), a novel oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 366
  start-page: 2443
  issue: 26
  year: 2012
  ident: 234
  article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
  publication-title: The New England journal of medicine
  doi: 10.1056/NEJMoa1200690
– volume: 16
  start-page: 3743
  issue: 14
  year: 2010
  ident: 196
  article-title: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-09-3352
– volume: 28
  start-page: 3965
  issue: 25
  year: 2010
  ident: 54
  article-title: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
  publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology
  doi: 10.1200/JCO.2009.26.7278
– year: 2013
  ident: 157
  article-title: Clinical, pathological and biological features associated with BRAF mutations in non-small cell lung cancer
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 3
  start-page: 548
  issue: 5
  year: 2013
  ident: 134
  article-title: Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer
  publication-title: Cancer discovery
  doi: 10.1158/2159-8290.CD-12-0446
– volume: 76
  start-page: 26
  issue: 1
  year: 2012
  ident: 62
  article-title: Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
  publication-title: Lung cancer
  doi: 10.1016/j.lungcan.2011.09.011
– volume: 71
  start-page: 2212
  issue: 6
  year: 2011
  ident: 184
  article-title: Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-10-3590
– volume: 83
  start-page: 407
  issue: 3
  year: 2012
  ident: 20
  article-title: Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence
  publication-title: Critical reviews in oncology/hematology
  doi: 10.1016/j.critrevonc.2011.11.010
– volume: 70
  start-page: 9827
  issue: 23
  year: 2010
  ident: 79
  article-title: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
  publication-title: Cancer research
  doi: 10.1158/0008-5472.CAN-10-1671
– volume: 6
  start-page: e20351
  issue: 6
  year: 2011
  ident: 127
  article-title: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer
  publication-title: PloS one
  doi: 10.1371/journal.pone.0020351
– volume: 2
  start-page: e39
  year: 2013
  ident: 50
  article-title: A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
  publication-title: Oncogenesis
  doi: 10.1038/oncsis.2013.4
– ident: 72
  doi: 10.1200/JCO.2013.50.8705
– volume: 62
  start-page: 3659
  issue: 13
  year: 2002
  ident: 168
  article-title: Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung
  publication-title: Cancer research
– year: 2013
  ident: 113
  article-title: Epithelial to mesenchymal transition rewires the molecular path to PI3-Kinase-dependent proliferation
  publication-title: Cancer discovery
– year: 2013
  ident: 162
  article-title: Identification of a Subset of Human Non-Small Cell Lung Cancer Patients with High PI3Kbeta and Low PTEN Expression, more prevalent in SCC
  publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research
– volume: 448
  start-page: 807
  issue: 7155
  year: 2007
  ident: 169
  article-title: LKB1 modulates lung cancer differentiation and metastasis
  publication-title: Nature
  doi: 10.1038/nature06030
– year: 2014
  ident: 148
  article-title: Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit
  publication-title: Cancer discovery
SSID ssj0000547829
Score 2.4752078
SecondaryResourceType review_article
Snippet Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1392
SubjectTerms Animals
Antineoplastic Agents - therapeutic use
Humans
Molecular Targeted Therapy
Neoplasm Proteins - antagonists & inhibitors
Neoplasm Proteins - metabolism
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - pathology
Review
Signal Transduction - drug effects
Title Molecular pathways and therapeutic targets in lung cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/24722523
https://www.proquest.com/docview/1529838998
https://pubmed.ncbi.nlm.nih.gov/PMC4039220
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LSwMxEA5aL15E8VUfJYIXD2t3s9lschARsRahniz0tuSJhbLVPtD-ezO729ZqEbzuJiH5kpBvMplvELo0Sqd-qUSBjK0IqCMuEMR5ImdpSJVQaWLgaqDzzNpd-tRLesvw6ArA8VrTDvJJdUeD68_32a3f8Dew4TmLSXMIOgbFw2n_AULZtwpvETzkq8h-qfRN_XEoCjczFYHn0nHlt1zXyOo59Yt8_nxD-e1Qau2inYpN4rty-vfQhs33kejMU95iyDf8IWdjLHODv4Va4bILY9zP8cBvd6xh8kcHqNt6eLlvB1WGhEBTRiYBU4kMJXcxp4I7wxRJnTaRUVEsKWc8lZEMNUt0alLm_ICN0CoNrWXEscTboIeolg9ze4ywpc54azUSSlG4bZMq1lpzFxpDotjZOmrO8ch0JR8OWSwGGZgRgGC2RDADBOvoalHjrZTO-KPsxRzizK9vcFrI3A6n48zzC8FBBJDX0VEJ-aI1AkqXfhR1lK5MxqIAaGev_sn7r4WGNg09MSThyT_6eIq2PVuiRUBieIZqk9HUnntGMlENtPnYixrFcvsC8lrl5Q
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+pathways+and+therapeutic+targets+in+lung+cancer&rft.jtitle=Oncotarget&rft.au=Shtivelman%2C+Emma&rft.au=Hensing%2C+Thomas&rft.au=Simon%2C+George+R.&rft.au=Dennis%2C+Phillip+A.&rft.date=2014-03-30&rft.issn=1949-2553&rft.eissn=1949-2553&rft.volume=5&rft.issue=6&rft.spage=1392&rft.epage=1433&rft_id=info:doi/10.18632%2Foncotarget.1891&rft.externalDBID=n%2Fa&rft.externalDocID=10_18632_oncotarget_1891
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon